Of note, CDK4/6 inhibitors regulate PD-L1 stability in tumor cells [53], augment cytotoxic T cell activation [21], and attenuate suppressive functions of regulatory T cells [22], all of which contribute to robust antitumor immunity with reinforced host immune surveillance. Here, CDK4 is linked to neoplasm.